Healthcare Professionals

Why Zensor™ device

Zensor™ device is the world’s first three lead, 14 days continuous ECG and remote event device available on the market. This small yet powerful system enables the transmission of comprehensive ECG data to allow you diagnose patient arrhythmias including Atrial Fibrillation. Cleared for use by the US FDA and CE marked, the Zensor™ device is a wi-fi enabled patient monitor that captures the electrical rhythm and the rate of your patient’s heart for up to 14 days.

Key

Features

  • 3 lead wi-fi enabled ECG monitoring system
  • Up to 14 day continuous beat by beat data capture and recording
  • Event transmission and near real time recording in one device
  • High quality data capture through use of proprietary motion artefact reducing electrodes
  • Patient activated event recording feature
  • Wi-fi enabled for data transmission

The Zensor™

Device Allows for

  • Diagnosis of five cardiac arrhythmias including Atrial Fibrillation
  • Remote monitoring of your patients
  • Recording and transmission of an ECG by a patient
  • Full generation of a report with up to 14 days of patient cardiac data
  • Easy patient use - small, lightweight, unobtrusive device

Clinical Evidence

Need to improve detection is paramount

The global burden of cardiac arrhythmias is huge. Patients with atrial fibrillation (AF) face an increased risk for stroke, dementia, heart failure and death¹. Atrial fibrillation (AF) is the most common arrhythmia encountered in clinical practice and is a global epidemic with an estimated worldwide prevalence in 2010 of almost 34 million people². The condition is expected to more than double over the next 35 years³, which underscores the huge burden of AF and the need for newer, more effective ways to improve its detection and treatment.

Many patients affected by AF are asymptomatics or experience brief episodes that could be wrongly attributed to other conditions. Individuals with AF that go unrecognised and so untreated are at an increased risk for stroke and overall mortality³. Holter monitors that typically monitors patients for 24-48 hours run the risk of not capturing AF in a significant proportion of your presenting patients.

Stroke is the second leading cause of disability in Europe and is the sixth leading cause worldwide4. Women have a higher lifetime risk of stroke than men: about one in five women and one in six men will suffer a stroke in their lifetime4,5. The number of stroke events in Europe is projected to rise from 1.1 million in 2000 to 1.5 million per year by 2025, largely due to the ageing populations6. In the EU, it is estimated that the annual economic cost of stroke is an estimated €27 billion, with an additional €11.1 billion related to informal patient care7. People with AF have a five times greater chance of having a stroke and up to 30% of all strokes result directly from AF8.

Clinical Evidence

Supporting Zensor™ Device

The Zensor™ device has been used to date in hundreds of patients in Europe and the US. At Tallaght University Hospital, Dublin, Ireland, a study was undertaken to identify high risk patients with AF. The device was proven to deliver a convenient and reliable method of diagnosing AF in a high risk population.

 

Dr Robert Kelly, Consultant Cardiologist and Dr Rónán Collins, Consultant Geriatrician and National Clinical Lead on Stroke, designed and executed a screening study to confirm the efficacy of screening patients with pre-existing associated risk factors using a number of criteria from the Wilson-Junger Criteria9 as set out in the WHO screening programme*.

  • 320 patients were screened
  • Patient population were
    • >60 years with two risk factors (heart failure, diabetes, hypertension)
    • >75 years with one risk factor (heart failure, diabetes or hypertension)
    • No history of AF or Transient Ischemic Attacks or Stroke
  • 14% detection rate (against expected 8%) of AF in high risk patients including those with diabetes, high blood pressure or congestive heart failure

 

Using Zensor™ device in this targeted screening approach produces a Number Needed to Screen (NSS)  of seven patients to identify one with AF.

 

*Community-based screening for the detection of Atrial Fibrillation in potentially high prevalence cohorts study at Tallaght University Hospital, Dublin, Ireland designed and lead by Dr Rónán Collins, National Stroke Lead, Ireland and Dr Robert Kelly, Consultant Cardiologist.

 

References.

1. Estes, N. A., Sacco, R. L,Al-Khatib, S. M., Ellinor, P. T., Bezanson,J.,Alonso,A., Benjamin, E.J. American Heart Association atrial fibrillation research summit: A conference report from the American Heart Association. Circulation, 2011, 124, 363-372.
2. Barnett Adam S, Lewis William R. Quality of Evidence Underlying the American Heart Association/American College of Cardiology/Heart Rhythm Society Guidelines on the Management of Atrial Fibrillation.JAMA Cardiol, 2017 Mar 01;2 (3):319-323.
3. January Craig T,Wann L Samuel AHA/ACC/HRS guideline for the management of patients with atrial fibrillation: a report of the American College of Cardiology/American Heart Association Task Force on practice guidelines and the Heart Rhythm Society. Circulation, 2014 Dec 02:130 (23):e199-267.
4.The Top Ten Causes of Death- Fact Sheet No. 310. Geneva,World Health Organization, 2011.
5 Seshadri S et aL The lifetime risk of stroke: estimates from the Framingham Study. Stroke, 2006, 37:345-350.
6. Truelsen T, Piechowski-Jozwiak B, Bonita R. Stroke incidence and prevalence in Europe: a review of available data. European Journal of Neurology, 2006, 13: 581-598.
7. British Geriatrics Society. Human and economic burden of stroke. Age and Ageing, 2009, 38: 4- 5.
8. Marini, C et aL Contribution of atrial fibrillation to incidence and prevalence of atrial fibrillation in the US adult population. American Journal of Medicine 2013,112(8);1142-7.
9. Wilson JMG,Jungner G. Principles and practice of screening for disease. Geneva: WHO; 1968. Available from: 

http://www.who.int/bulletin/volumes/86/4/07-050112BP.pdf

Compliance and Feedback

The patient friendly Zensor™ device facilitates high patient compliance. With minimal set up and maintenance required by the patient, all the data you need will be collected and collated for you over a single monitoring period.

Clinician and patient feedback for the Zensor™ device has been overwhelmingly positive – here is a just selection of the positive feedback we have received from both clinicians and patients.

Health professional and end user feedback

Clinical

  • Very useful for quick diagnosis
  • Patients have been positive about the experience
  • State of the art device, which is compact and easy to wear for the patients
  • Easy to use for clinical staff and patients

Patient

  • A very positive and quick way to be diagnosed
  • After a dry or two I did not notice wearing it
  • I felt confident using the Zensor™ device
  • The device was fine to wear, forgot it was on most of the time
  • It is a good idea to have a device which you can use in real time
  • Clinician and patient feedback disclosed in this booklet was captured as part of a Zensor™ device evaluation at South Eastern Health and Social Care Trust, Northern Ireland and a Stroke Prevention study.

Add Zensor™

to Your Practice

The Zensor™ device is a complete system solution to allow you to measure and record a patient’s heart rhythm for up 14 days. As well as continually capturing and recording beat by beat data for your patient,this unique device can, should you choose, capture patient activated events on a daily basis. By recording a patient’s heart rhythm continuously for up to 14 days,as well as capturing daily events, you may be able to make quick clinical decisions, reduce number of tests you need to undertake and quickly put your patient on an effective treatment pathway.

4 Simple Steps

for quicker diagnosis

Step 1

Zensor™ Device assigned, placed on patient and activated.

Step 2

Data transmits to Zensor™ Device monitoring centre where data is captured.

Step 3

After 14 days (or earlier if Clinician chooses) patient returns device to Clinician for processing in device monitoring centre.

Step 4

Report sent back to Clinician to support diagnosis.

Device Specifications

The Zensor™device sets a new standard for cardiac monitoring with extended ambulatory monitoring together with event capture in near real time for a comprehensive and timely read out of your patient’s cardiac data.

 

For detail on the device specifications, please click button below.

Learn More

Training

and Support

To have the best possible experience with your Zensor™ device, we will support you every step of the way. Our dedicated team of clinical experts and customer support staff are there to help you incorporate the Zensor™ device into your practice so that you can diagnose your at-risk patients as quickly as possible.

Patient

Frequently Asked Questions